Vaith P, Maas D, Feigl D, Hauke G, Lang B, Oepke G, Stierle H E, Bross K J, Andreesen R, Gross G
Immun Infekt. 1985 Apr;13(2):51-63.
We report on a lethal course of an acquired immunodeficiency syndrome (AIDS) in a young female patient. She had spent her vacancies six years before diagnosis in Haiti, where a sexual intercourse with a Haitian man had occurred. Leading clinical symptoms consisted of recurrent Herpes simplex infections of the genital and perianal region as well as unexplained high temperatures. There were some typical laboratory and immunologic features of this disease with leukopenia, hypergammaglobulinemia, cutaneous anergy, a reduction of peripheral T-lymphocytes (OKT 3) and an almost complete loss of OKT 4 (helper cells) positive lymphocytes. The mitogenic response upon stimulation with allogeneic cells (MLC) or with the mitogens PHA, Con A and PWM was significantly reduced. There was no measurable interleukin-2 (IL-2) secretion of peripheral blood lymphocytes. Several immunostimulators (thymopentin, inosiplex, bestatin) were tested in lymphocyte proliferation assays in vitro. The mitogenic response could not be enhanced by neither of these substances. A clinical trial with Delimmun (inosiplex) for 14 days did not show any clinical or immunologic improvement in this patient. The intravenous application of high dose immunoglobulin G was without any observable effect. The proliferation inducing capacity of a highly purified IL-2 preparation on the AIDS cells in vitro led us to a clinical trial with this substance. We applied 100 Bödeker units of IL-2 per kg body weight and day subcutaneously for 16 days. A therapeutical effect, however, could not be observed. Cell marker analyses did not show significant changes in lymphocyte subpopulation composition under IL-2 therapy. There was an increase in the spontaneous cell proliferation 14 days after start of IL-2 therapy. The PHA- and IL-2 response of the AIDS cells, however, was unchanged. It cannot be excluded that an administration of IL-2 in earlier stages of AIDS may have beneficial effects.
我们报告了一名年轻女性获得性免疫缺陷综合征（艾滋病）患者的致死病程。在确诊前六年，她曾在海地度假，期间与一名海地男子发生过性行为。主要临床症状包括生殖器和肛周区域反复出现单纯疱疹感染以及不明原因的高热。该疾病具有一些典型的实验室和免疫学特征，如白细胞减少、高球蛋白血症、皮肤无反应性、外周血T淋巴细胞（OKT 3）减少以及OKT 4（辅助细胞）阳性淋巴细胞几乎完全丧失。用异基因细胞（混合淋巴细胞培养，MLC）或丝裂原PHA、Con A和PWM刺激后的促有丝分裂反应显著降低。外周血淋巴细胞无可检测到的白细胞介素-2（IL-2）分泌。在体外淋巴细胞增殖试验中测试了几种免疫刺激剂（胸腺喷丁、肌苷多聚磷酸酯、贝司他汀）。这些物质均不能增强促有丝分裂反应。对该患者进行了为期14天的聚肌胞苷酸（肌苷多聚磷酸酯）临床试验，未显示出任何临床或免疫学改善。静脉应用高剂量免疫球蛋白G没有任何可观察到的效果。一种高度纯化的IL-2制剂在体外对艾滋病细胞的增殖诱导能力促使我们对该物质进行临床试验。我们按每千克体重每天皮下注射100博德克单位的IL-2，共16天。然而，未观察到治疗效果。细胞标志物分析未显示IL-2治疗下淋巴细胞亚群组成有显著变化。IL-2治疗开始14天后自发细胞增殖有所增加。然而，艾滋病细胞对PHA和IL-2的反应未改变。不能排除在艾滋病早期给予IL-2可能有有益效果。
